论文部分内容阅读
类风湿关节炎是以滑膜炎、慢性系统性炎症反应及自身抗体分泌为特点的自身免疫性疾病。已有研究结果表明,过量表达的IL-6在类风湿关节炎起病与进展过程中发挥着重要作用。Tolicizumab是第1个人源性的IL-6受体抗体,通过特异性识别结合IL-6受体而阻断IL-6生物学活性,发挥抑制类风湿关节炎炎症反应的作用。大量临床试验证据表明,tocilizumab不仅能明显缓解类风湿关节炎的临床症状,而且能防止关节继续遭受破坏。
Rheumatoid arthritis is an autoimmune disease characterized by synovitis, chronic systemic inflammatory reactions, and autoantibodies. Previous studies have shown that overexpression of IL-6 plays an important role in the pathogenesis and progression of rheumatoid arthritis. Tolicizumab is the first human-derived IL-6 receptor antibody that blocks the IL-6 biological activity by specifically recognizing the binding to the IL-6 receptor and exerts an anti-rheumatoid arthritis inflammatory response. Numerous clinical trials have shown that tocilizumab not only significantly relieves the clinical symptoms of rheumatoid arthritis but also prevents the joint from continuing to suffer damage.